JP4533535B2 - Tan−1057誘導体 - Google Patents

Tan−1057誘導体 Download PDF

Info

Publication number
JP4533535B2
JP4533535B2 JP2000567514A JP2000567514A JP4533535B2 JP 4533535 B2 JP4533535 B2 JP 4533535B2 JP 2000567514 A JP2000567514 A JP 2000567514A JP 2000567514 A JP2000567514 A JP 2000567514A JP 4533535 B2 JP4533535 B2 JP 4533535B2
Authority
JP
Japan
Prior art keywords
group
formula
mmol
amino
embedded image
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000567514A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002523496A5 (enExample
JP2002523496A (ja
Inventor
ブランズ,ミヒヤエル
エス−ザエト,マツエン
ヘビヒ,デイーター
ラダツ,ジークフリート
クリユガー,ヨアヒム
エンデルマン,ライナー
ガールマン,ラインホルト
クロル,ハイン−ペーター
ゲシユケ,フランク−ウルリヒ
デ・メイジエレ,アルミン
ベロフ,ウラデイミル・エヌ
ソコロフ,ビクトル
コズフシユコフ,セルゲイ
コルデス,マルクス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of JP2002523496A publication Critical patent/JP2002523496A/ja
Publication of JP2002523496A5 publication Critical patent/JP2002523496A5/ja
Application granted granted Critical
Publication of JP4533535B2 publication Critical patent/JP4533535B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44Nitrogen atoms not forming part of a nitro radical
    • C07D233/48Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
JP2000567514A 1998-08-27 1999-08-20 Tan−1057誘導体 Expired - Fee Related JP4533535B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19838998A DE19838998A1 (de) 1998-08-27 1998-08-27 Neue Naturstoffderivate
DE19838998.1 1998-08-27
PCT/EP1999/006124 WO2000012484A1 (de) 1998-08-27 1999-08-20 Tan-1057 derivate

Publications (3)

Publication Number Publication Date
JP2002523496A JP2002523496A (ja) 2002-07-30
JP2002523496A5 JP2002523496A5 (enExample) 2006-08-10
JP4533535B2 true JP4533535B2 (ja) 2010-09-01

Family

ID=7878913

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000567514A Expired - Fee Related JP4533535B2 (ja) 1998-08-27 1999-08-20 Tan−1057誘導体

Country Status (25)

Country Link
US (1) US6617332B1 (enExample)
EP (1) EP1117652B1 (enExample)
JP (1) JP4533535B2 (enExample)
KR (1) KR20010099629A (enExample)
CN (1) CN1324348A (enExample)
AT (1) ATE267816T1 (enExample)
AU (1) AU759618B2 (enExample)
BG (1) BG105275A (enExample)
BR (1) BR9913337A (enExample)
CA (1) CA2342102C (enExample)
DE (2) DE19838998A1 (enExample)
EE (1) EE200100125A (enExample)
ES (1) ES2219105T3 (enExample)
HK (1) HK1041884A1 (enExample)
HR (1) HRP20010135A2 (enExample)
HU (1) HUP0103316A3 (enExample)
ID (1) ID28365A (enExample)
IL (1) IL141325A0 (enExample)
NO (1) NO20010940L (enExample)
NZ (1) NZ510153A (enExample)
PL (1) PL346143A1 (enExample)
SK (1) SK2622001A3 (enExample)
TR (1) TR200100637T2 (enExample)
WO (1) WO2000012484A1 (enExample)
ZA (1) ZA200101038B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1113008A1 (en) * 1999-12-29 2001-07-04 Pfizer Products Inc. 4-oxo-2-ureido-1,4,5,6-tetrahydro-pyrimidine derivatives useful as antibacterial and antiprotozoal agents
US20040204404A1 (en) * 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
US8309724B2 (en) * 2007-12-20 2012-11-13 Dr. Reddy's Laboratories Limited Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
WO2011046007A1 (ja) 2009-10-15 2011-04-21 国立大学法人徳島大学 ジエチレントリアミン五酢酸誘導体の製造方法およびジエチレントリアミン五酢酸誘導体
CN102725274A (zh) * 2009-10-16 2012-10-10 Rib-X制药公司 抗微生物化合物和其制备和使用方法
NZ599289A (en) 2009-10-16 2014-11-28 Melinta Therapeutics Inc Antimicrobial compounds and methods of making and using the same
KR20190044136A (ko) 2009-10-16 2019-04-29 멜린타 서브시디어리 코프. 항미생물성 화합물 및 이의 제조 방법 및 사용 방법
KR20120099435A (ko) * 2009-10-16 2012-09-10 립-엑스 파마슈티칼즈, 인크. 항미생물성 화합물 및 이의 제조 방법 및 사용 방법
EA201391536A1 (ru) 2011-04-15 2014-08-29 Мелинта Терапьютикс, Инк. Противомикробные соединения и способы их получения и применения
RU2475479C1 (ru) * 2011-12-23 2013-02-20 Федеральное государственное бюджетное учреждение Министерства здравоохранения и социального развития Российской Федерации "Медицинский радиологический научный центр" (ФГБУ МРНЦ Минздравсоцразвития России) Вазоконстрикторное средство
SG10201801956SA (en) 2013-09-09 2018-04-27 Melinta Therapeutics Inc Antimicrobial compounds and methods of making and using the same
EP3038623A4 (en) 2013-09-09 2017-04-19 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
JP2018507881A (ja) 2015-03-11 2018-03-22 メリンタ セラピューティクス,インコーポレイテッド 抗微生物化合物ならびにこれらを作製および使用する方法
CA3023317A1 (en) 2016-05-06 2017-11-09 Melinta Therapeutics, Inc. Antimicrobials and methods of making and using same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2873340B2 (ja) * 1988-04-29 1999-03-24 武田薬品工業株式会社 抗生物質tan―1057,その製造法および用途
US6110925A (en) 1997-08-07 2000-08-29 Research Corporation Technologies, Inc. Antibiotic for methicillin resistant bacteria

Also Published As

Publication number Publication date
WO2000012484A1 (de) 2000-03-09
ES2219105T3 (es) 2004-11-16
CA2342102A1 (en) 2000-03-09
HK1041884A1 (zh) 2002-07-26
AU759618B2 (en) 2003-04-17
ZA200101038B (en) 2002-02-07
DE19838998A1 (de) 2000-03-09
US6617332B1 (en) 2003-09-09
EP1117652B1 (de) 2004-05-26
ID28365A (id) 2001-05-17
HRP20010135A2 (en) 2002-02-28
NZ510153A (en) 2002-12-20
BR9913337A (pt) 2001-05-15
IL141325A0 (en) 2002-03-10
EE200100125A (et) 2002-06-17
NO20010940D0 (no) 2001-02-23
NO20010940L (no) 2001-04-23
BG105275A (en) 2001-11-30
ATE267816T1 (de) 2004-06-15
PL346143A1 (en) 2002-01-28
CA2342102C (en) 2008-10-28
EP1117652A1 (de) 2001-07-25
HUP0103316A2 (hu) 2002-04-29
AU1009900A (en) 2000-03-21
JP2002523496A (ja) 2002-07-30
HUP0103316A3 (en) 2002-06-28
KR20010099629A (ko) 2001-11-09
SK2622001A3 (en) 2001-11-06
TR200100637T2 (tr) 2001-10-22
DE59909607D1 (de) 2004-07-01
CN1324348A (zh) 2001-11-28

Similar Documents

Publication Publication Date Title
RU2266901C2 (ru) 4-пиримидинил-n-ацил-l-фенилаланины и фармацевтическая композиция
JP4533535B2 (ja) Tan−1057誘導体
TW201930291A (zh) 磺醯脲衍生物
CZ290445B6 (cs) Urethany a močoviny, způsoby jejich přípravy a farmaceutické přípravky na jejich bázi
AU2022201724B9 (en) Macrocyclic broad spectrum antibiotics
TW201617362A (zh) 化合物
JPH0820597A (ja) トロンビン阻害作用を有する複素環カルボニル化合物
CN104011019A (zh) 新的吡咯衍生物
TW202200582A (zh) Cbp/連環蛋白訊息傳遞路徑抑制劑及其用途
CA3191410A1 (en) Sulphamoyl urea derivatives containing alkyl-oxacycloalkyl moiety and uses thereof
CN114641466B (zh) 磺酰脲衍生物及其用途
CN114761383A (zh) 磺酰胺衍生物及其用途
CN113660983A (zh) 氨基甲酸酯衍生物及其用途
CN114401970A (zh) 铁载体头孢菌素缀合物及其用途
JP2004137185A (ja) チオフェン骨格を有する抗菌剤
CZ2001742A3 (cs) Nové deriváty přírodních látek
KR100388785B1 (ko) (3-아미노-4-알킬옥심)피페리딘 치환체를 갖는 신규한 퀴놀론 카
MXPA01002058A (en) Tan-1057 derivatives
HK40082400A (en) Cbp/catenin signaling pathway inhibitors and uses thereof
JPH0570467A (ja) アミノ酸置換チアゼトキノリン−3−カルボン酸誘導体
HK40031620A (en) Selective inhibitors of nlrp3 inflammasome
HK40031620B (en) Selective inhibitors of nlrp3 inflammasome
JP2014101276A (ja) Muraymycin誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060623

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060623

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080328

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100210

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100510

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100608

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100614

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130618

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130618

Year of fee payment: 3

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130618

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees